RNS-60 is under clinical development by Revalesio and currently in Phase II for Acute Ischemic Stroke. According to GlobalData, Phase II drugs for Acute Ischemic Stroke have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RNS-60’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RNS-60 overview
RNS-60 is under development for the treatment of acute ischemic stroke, traumatic brain injury, amyotrophic lateral sclerosis, relapsing-remitting multiple sclerosis, Parkinson’s disease and Alzheimer's disease. The drug candidate consists of normal saline solution oxygenated under the Taylor-Couette-Poiseuille (TCP) flow, creating charge-stabilized nano-structures (CSN) or oxygen nanobubbles. The chemical composition of RNS60 is water, sodium chloride (0.9 percent), and oxygen (55 plus or minus 5 ppm). It is administered through inhalation and intravenous routes. The drug candidate was also under development for myocardial infarction and mild to moderate allergic asthma.
Revalesio overview
Revalesio is a developer of novel therapeutics for the treatment of inflammatory diseases. The company conducts research and development activities to develop therapeutics in the areas of respiratory, neuroscience and cardiovascular. Its product pipeline includes drugs targeted on asthma, Parkinson’s disease and acute myocardial infarctions, among others. Revalesio develops RNS60 a processing normal, medical-grade, isotonic saline, which is used as an ingredient in the development of therapeutics through its proprietary charge-stabilized nanostructure technology. Revalesio is headquartered in Tacoma, Washington, the US.
For a complete picture of RNS-60’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
